Name and address of the site: Norsk Medisinaldepot AS
(ORG-100013274 / LOC-100018522)
, Alf Bjerckes Vei 28, Oslo, 0596, Norway
Human medicinal products
Veterinary medicinal products
1. MEDICINAL PRODUCTS
1.1. with a Marketing Authorisation or registration in EEA country(s)
1.2. without a Marketing Authorisation or registration in the EEA and intended for EEA market*
1.3. without a Marketing Authorisation or registration in the EEA and intended for exportation
|
2. AUTHORISED WHOLESALE DISTRIBUTION OPERATIONS
2.1. Procurement
2.2. Holding
2.3. Supply
2.4. Export
2.5. Other activities(s): (please specify) Storage of unreleased medicinal products in quarantine.
|
3. MEDICINAL PRODUCTS WITH ADDITIONAL REQUIREMENTS
3.1. Narcotic or psychotropic products**
3.2. Products requiring low temperature handling
3.2.1. Temperatures between 2 to 8 °C
3.2.2. Other temperatures: (please specify) Minus 10 to minus 25 degrees Celscius
3.3. Other products: (please specify here or make a reference to Annex 5) API | Medicinal products derived from blood | Immunological medicinal products
|
Any restrictions or clarifying remarks (for all users): Section 1.2 applies only to: • For human medicinal products: Medicinal products for which NoMA has granted an exemption from the requirement for marketing authorisation (MA) through approval for compassionate use, named patient (CUNP), under current regulations, cf. the Medicines Regulation § 2-5, or authorisation for the sale of foreign language packages in a shortage situation. • For veterinary medicinal products: Medicinal products for which NoMA has granted an exemption from the requirement for MA, cf. the Regulation on Medicines for Animals, Chapter 4 and § 11-2, the Medicines Act § 2 d last paragraph, and Regulation 2019/6/EU Articles 112-114.
The above-mentioned medicinal products are limited to patients/animals in Norway who/that have been granted such exemptions.
For more specific details; see restrictions or clarifying remarks in WDA issued by NoMA.
Section 2.2 also includes holding on behalf of other companies.
*Art. 5 of Directive 2001/83/EC, Art. 83 of Regulation (EC) 726/2004 and Art. 110 of Regulation 2019/6.
**Without prejudice to further authorisations as may be required according to national legislation.
|